| Drugs by Condition |  |
Diabetes, Type 2 Medications
Definition of Diabetes, Type 2: Type 2 diabetes is characterized by "insulin resistance" as body cells do not respond appropriately when insulin is present. This is a more complex problem than type 1, but is sometimes easier to treat, since insulin is still produced, especially in the initial years. Type 2 may go unnoticed for years in a patient before diagnosis, since the symptoms are typically milder (no ketoacidosis) and can be sporadic. However, severe complications can result from unnoticed type 2 diabetes, including renal failure, and coronary artery disease. Type 2 diabetes was formerly known by a variety of partially misleading names, including "adult-onset diabetes", "obesity-related diabetes", "insulin-resistant diabetes", or "non-insulin-dependent diabetes" (NIDDM). It may be caused by a number of diseases, such as hemochromatosis and polycystic ovary syndrome, and can also be caused by certain types of medications (e.g. long-term steroid use). About 90-95% of all North American cases of diabetes are type 2, and about 20% of the population over the age of 65 is a type 2 diabetic. The fraction of type 2 diabetics in other parts of the world varies substantially, almost certainly for environmental and lifestyle reasons. There is also a strong inheritable genetic connection in type 2 diabetes: having relatives (especially first degree) with type 2 is a considerable risk factor for developing type 2 diabetes. The majority of patients with type 2 diabetes mellitus are obese - chronic obesity leads to increased insulin resistance that can develop into diabetes, most likely because adipose tissue is a (recently identified) source of chemical signals (hormones and cytokines).
Drugs (by generic name) associated with Diabetes, Type 2
The following drugs and medications are in some way related to, or used in the treatment of Diabetes, Type 2. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
See also...
Diabetes, Type 2 Medications in the Pipeline
- February 26, 2007 - Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue ''Approvable Letter''
- November 13, 2006 - Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue "Approvable Letter"
- March 30, 2006 - New drug application for Galvus, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA
- October 27, 2005 - Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment For Type 2 Diabetes
- October 18, 2005 - Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
- September 9, 2005 - Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
- December 23, 2004 - Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar
- August 28, 2009 - Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
- June 28, 2009 - Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
- March 6, 2009 - Takeda Receives New Information on Alogliptin (SYR-322) NDA
- December 24, 2008 - Takeda Receives New Action Date for Alogliptin (SYR-322) NDA
- October 10, 2008 - FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
- February 29, 2008 - PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration
- January 4, 2008 - Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
- April 30, 2008 - Spherix D-tagatose to be Supplied by Inalco SpA
- September 4, 2009 - Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes
- July 23, 2009 - Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl)
- September 24, 2008 - Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Latest Diabetes, Type 2 Blog Post
Older Diabetics Should Avoid Dementia Meds
TUESDAY, July 28 -- Older diabetics who take antipsychotic medications have an increased risk of ending up in the hospital with elevated blood glucose levels, or hyperglycemia, researchers say.
More and more seniors are being prescribed these medications...
View all Diabetes, Type 2 blog posts.
Diabetes, Type 2 Support Group Questions
- How much water should I drink in a day when I have kidney failure?
- Glimepiride/Pioglitazone - whicher is better choice betweenglimprideandpioglitazone?
- Is the metformin SR tablets is agood replacement of metformin Retard tablets,...
- I am taking Glimepiride and I have gain 30 pound in 60 day... can this...
- Can I cut metformin 500 mg pill in half? I'm feeling better, do I need...
Go to the Diabetes, Type 2 support group or view all Diabetes, Type 2 questions.
Ask a Question about Diabetes, Type 2:
Learn more about Diabetes, Type 2
Medical encyclopedia results for:
